For Healthcare Professionals

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

clipboard-pencil

About the study

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab plus best supportive care or matching placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1, and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week follow-up period.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. 12 years of age or older at time of consent/assent.
  2. Received HSCT within the past 12 months
  3. Diagnosis of TMA that persists for at least 72 hours despite initial management
  4. A TMA diagnosis based on meeting the select criteria during the Screening Period and/or <=14 days prior to the Screening Period.
  5. Body weight ≥ 30 kilograms at Screening.
  6. Female participants of childbearing potential and male participants with female partners of childbearing potential must use highly effective contraception.
  7. Participants must be vaccinated against meningococcal infections if clinically feasible. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis.
  8. Participants or their legally authorized representative must be capable of giving signed informed consent or assent

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Thrombotic thrombocytopenic purpura (TTP) evidenced by ADAMTS13 deficiency
  2. Shiga toxin producing Escherichia coli infection
  3. Positive direct Coombs test.
  4. Clinical diagnosis of disseminated intravascular coagulation (DIC).
  5. Known bone marrow/graft failure.
  6. Diagnosis of veno-occlusive disease.
  7. Human immunodeficiency virus (HIV) infection.
  8. Unresolved meningococcal disease.
  9. Presence of sepsis requiring vasopressor support.
  10. Pregnancy or breastfeeding.
  11. Previously or currently treated with a complement inhibitor.
  12. Respiratory failure requiring mechanical ventilation.
  13. Acute and/or chronic heart failure.
  14. Participation in an interventional treatment study of any therapy for TMA.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Thrombotic Microangiopathy

Age (in years)

12+

Phase

Phase 3

Participants needed

114

Est. Completion Date

Jun 30, 2025

Treatment type

Interventional


Sponsor

Alexion Pharmaceuticals, Inc.

ClinicalTrials.gov identifier

NCT04543591

Study number

ALXN1210-TMA-313

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.